A New Era in Geographic Atrophy Clinical Trials

Geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD), is entering a transformative phase in research and treatment development. While recent approvals of complement inhibitors mark an important step forward, challenges remain in patient selection, trial design, and achieving meaningful functional outcomes.

Advances in genetic profiling, imaging biomarkers, and AI-driven predictive modeling are opening the door to a precision-based approach—one that can enhance recruitment, optimize endpoints, and improve the chances of delivering therapies that truly change lives.

This white paper explores how integrating genetics, smarter endpoints, and artificial intelligence can reshape the future of GA research. You’ll gain strategic insights into overcoming long-standing trial challenges and designing studies that are more efficient, adaptive, and patient-focused.

Inside the white paper:

• How genetic profiling can improve patient selection and trial success rates
• The role of alternative complement pathway variants in GA progression
• Emerging therapeutic strategies, including gene, cell, and combination therapies
• Advanced imaging biomarkers and AI tools that can detect and predict GA progression
• The importance of composite endpoints and patient-reported outcomes in trial design
• Practical solutions to common recruitment, retention, and endpoint variability challenges

Download the white paper today and discover how to apply the latest science, technology, and patient-centered strategies to your geographic atrophy clinical trials.

Learn more about our related services and resources:

TFS Ophthalmology